A. Ishihara

发表

Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice.

H. Iwaasa, H. Matsushita, A. Kanatani, 2009, Endocrinology.

Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.

H. Iwaasa, S. Sakuraba, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Characterization of MCH-mediated obesity in mice.

H. Iwaasa, H. Matsushita, A. Kanatani, 2003, American journal of physiology. Endocrinology and metabolism.

Chronic intracerebroventricular infusion of MCH causes obesity in mice. Melanin-concentrating hormone.

H. Iwaasa, H. Matsushita, A. Kanatani, 2003, American journal of physiology. Endocrinology and metabolism.

Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists.

H. Iwaasa, A. Kanatani, Masahiko Ito, 2011, Bioorganic & medicinal chemistry.

L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2000, Biochemical and biophysical research communications.

Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.

M. Hirose, N. Fujino, A. Kanatani, 2003, Journal of medicinal chemistry.

Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice

H. Iwaasa, A. Kanatani, Y. Mitobe, 2009, Peptides.

NPY-induced feeding involves the action of a Y1-like receptor in rodents

D. Macneil, H. Iwaasa, A. Kanatani, 1998, Regulatory Peptides.

The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.

T. Tanaka, M. Hata, A. Kanatani, 1999, Biochemical and biophysical research communications.

A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814.

T. Ohe, M. Hata, A. Kanatani, 2001, Molecular pharmacology.

Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high‐fat diet

H. Iwaasa, A. Kanatani, Makoto Ito, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice.

H. Iwaasa, Keiko Watanabe, A. Kanatani, 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

Neuropeptide Y receptors as targets of obesity treatment

D. Macneil, A. Kanatani, T. Fukami, 2006 .

Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice.

M. Bednarek, D. Macneil, H. Iwaasa, 2008, The Journal of endocrinology.

Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake.

T. Tanaka, A. Kanatani, A. Ishihara, 1996, Endocrinology.

Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice

M. Bednarek, D. Macneil, H. Iwaasa, 2007, British journal of pharmacology.

Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.

H. Iwaasa, H. Matsushita, A. Kanatani, 2009, European journal of pharmacology.

Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY.

N. Morin, D. Macneil, H. Iwaasa, 2003, Endocrinology.

Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.

H. Iwaasa, M. Ando, T. Ohe, 2009, Journal of medicinal chemistry.

Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine

D. Macneil, H. Iwaasa, H. Matsushita, 2008, Obesity.

Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.

D. Macneil, R. Yoshimoto, Takao Nakamura, 2006, European journal of pharmacology.

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Y. Mitobe, 2008, Journal of medicinal chemistry.

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.

H. Iwaasa, M. Ando, M. Ishikawa, 2009, Bioorganic & medicinal chemistry.

Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.

H. Iwaasa, T. Ohe, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.

H. Iwaasa, H. Matsushita, M. Ando, 2009, Bioorganic & medicinal chemistry.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.

H. Iwaasa, K. Matsuda, M. Ishikawa, 2008, Bioorganic & medicinal chemistry letters.

A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2007, Molecular Pharmacology.

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2006, Proceedings of the National Academy of Sciences of the United States of America.

[Development of anorectic NPY antagonists: possible roles of Y1 and Y5 receptors in feeding regulation].

D. Macneil, H. Iwaasa, A. Kanatani, 2006, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist

Keiko Watanabe, M. Hata, A. Kanatani, 2002, British journal of pharmacology.

A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats.

T. Tanaka, A. Kanatani, T. Fukami, 1998, The American journal of physiology.

Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.

H. Iwaasa, M. Ando, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.

H. Iwaasa, M. Ando, T. Ohe, 2008, Journal of medicinal chemistry.

Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists.

H. Iwaasa, M. Ishikawa, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography.

R. Yoshimoto, H. Kotani, A. Kanatani, 2004, Analytical biochemistry.

Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Shigeru Tokita, Shiho Ishikawa, Akane Ishihara, 2008, Journal of medicinal chemistry.

Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus

D. Macneil, R. Yoshimoto, H. Kotani, 2006, Proceedings of the National Academy of Sciences.

Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice*

H. Kotani, S. Mizuarai, H. Itadani, 2003, Journal of Biological Chemistry.

Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R

Christopher P. Austin, Masahiko Ito, Alka Bansal, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.

H. Iwaasa, M. Ando, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Mechanism of the anti‐obesity effects induced by a novel Melanin‐concentrating hormone 1‐receptor antagonist in mice

D. Macneil, H. Iwaasa, A. Kanatani, 2010, British journal of pharmacology.

Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.

Kouta Masutani, M. Kameda, H. Matsushita, 2009, Bioorganic & medicinal chemistry letters.

Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists.

H. Iwaasa, S. Sakuraba, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Identification and characterization of a selective radioligand for melanin-concentrating hormone 1-receptor (MCH1R).

H. Iwaasa, H. Matsushita, D. Dean, 2009, Bioorganic & medicinal chemistry letters.

Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.

M. Bednarek, D. Macneil, H. Iwaasa, 2005, Endocrinology.

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

H. Iwaasa, T. Ohe, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.

D. Macneil, H. Iwaasa, A. Kanatani, 2009, Bioorganic & Medicinal Chemistry Letters.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.

H. Iwaasa, A. Kanatani, T. Fukami, 2009, Bioorganic & medicinal chemistry.

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.

H. Iwaasa, K. Matsuda, M. Ishikawa, 2008, Bioorganic & medicinal chemistry letters.

RFamide peptide QRFP43 causes obesity with hyperphagia and reduced thermogenesis in mice.

H. Iwaasa, A. Kanatani, Yuki Takahashi, 2006, Endocrinology.

Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors

H. Iwaasa, T. Iwama, A. Kanatani, 2001, Peptides.

Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice.

D. Macneil, H. Iwaasa, H. Matsushita, 2009, European journal of pharmacology.

rapid communication A potent neuropeptide Y antagonist , 1229 U 91 , suppressed spontaneous food intake in Zucker fatty rats

A. Kanatani, T. Fukami, A. Ishihara, 1998 .

A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats.

A. Kanatani, T. Fukami, A. Ishihara, 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice.

M. Bednarek, D. Macneil, H. Iwaasa, 2008, The Journal of endocrinology.

Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus

D. Macneil, R. Yoshimoto, H. Kotani, 2006, Proceedings of the National Academy of Sciences.

H. Iwaasa, M. Ando, T. Ohe, 2009, Journal of medicinal chemistry.

Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.

M. Bednarek, D. Macneil, H. Iwaasa, 2005, Endocrinology.

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Sayaka Ito, 2008, Journal of medicinal chemistry.

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

H. Iwaasa, T. Ohe, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.